ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios...
ATLANTA, May 19, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios...
ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios...
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring...
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a...
- New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally –...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.